세계의 퇴행성 추간판(DDD) 치료 시장 : 규모, 점유율, 동향 분석 - 투여 경로별, 약제별, 최종 용도별, 치료 유형별, 지역별 전망과 예측(2024-2031년)

The Global Degenerative Disc Disease Treatment Market size is expected to reach $42.5 billion by 2031, rising at a market growth of 5.3% CAGR during the forecast period.

Many countries in the Asia-Pacific region have made significant investments in healthcare infrastructure, expanding access to specialized medical facilities, spine centers, and rehabilitation clinics equipped with advanced diagnostic technologies and treatment modalities for managing DDD. Consequently, the Asia Pacific region would acquire nearly 25% of the total market share by 2031.

Increased awareness leads to earlier recognition of symptoms and encourages individuals to seek medical advice sooner. In addition, greater awareness often spurs investments in diagnostic technologies, such as MRI scans, CT scans, and other imaging modalities. Thus, the rising awareness and early diagnosis of spinal disorders drive the market's growth. Additionally, Higher healthcare spending allows healthcare systems to invest in advanced treatment options for degenerative disc disease. Increased funding enables the expansion and modernization of healthcare facilities, including specialized centers for spinal health.

However, the high cost of advanced treatments such as minimally invasive surgeries, biologic therapies, and regenerative medicine can be prohibitive for many patients. Many insurance providers may not cover the full cost of advanced DDD treatments or may have stringent criteria for coverage approval. Hence, high treatment costs are impeding the growth of the market.

Moreover, Restrictions on international and domestic logistics disrupted the supply chain for medical devices and pharmaceuticals used in DDD treatments. This led to shortages and delayed availability of necessary treatment options. Economic uncertainties caused by the pandemic led to financial constraints for healthcare providers and patients. Thus, the COVID-19 pandemic had a negative impact on the market.

Route of Administration Outlook

By route of administration, the market is segmented into injectable and oral. The injectable segment procured a 35% revenue share in the degenerative disc disease treatment market in 2023. Injectables allow for direct delivery of medications to specific sites within the spine affected by DDD.

Drugs Outlook

Based on drugs, the degenerative is divided into acetaminophen, NSAIDs (non-steroidal anti-inflammatory drugs), muscle relaxants, and steroids. The muscle relaxants segment attained a 22% revenue share in the degenerative disc disease treatment market in 2023. Muscle relaxants are effective in relieving muscle spasms, which are common symptoms of DDD.

End Use Outlook

Based on end use, the market is categorized into hospitals, clinics, and others. The clinics segment witnessed 34% growth rate in the degenerative disc disease treatment market in 2023. Clinics provide accessible healthcare services in community settings, making it easier for patients with DDD to seek timely medical attention and treatment close to their homes.

Treatment Type Outlook

On the basis of treatment type, the market is segmented into occupational therapy, physical therapy, special exercises, medications, and weight loss surgery. In 2023, the occupational therapy segment attained 22% revenue share in the degenerative disc disease treatment market. Occupational therapy focuses on enhancing a person's ability to perform activities of daily living (ADLs) independently and safely.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed 40% revenue share in the market in 2023. In North America, sedentary lifestyles are common, marked by extended periods of sitting, inadequate physical activity, and poor posture.

List of Key Companies Profiled

• Medtronic PLC
• AstraZeneca PLC
• Pfizer, Inc.
• Novartis AG
• Eli Lilly And Company
• Spine Wave Inc.
• B. Braun Melsungen AG (Aesculap, Inc.)
• DiscGenics, Inc.
• Spine BioPharma Inc.
• Stryker Corporation

Global Degenerative Disc Disease Treatment Market Report Segmentation

By Route of Administration

• Oral
• Injectable

By Drugs

• NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
• Acetaminophen
• Muscle Relaxants
• Steroids

By End Use

• Hospitals
• Clinics
• Others

By Treatment Type

• Physical Therapy
• Occupational Therapy
• Special Exercises
• Weight Loss Surgery
• Medications

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Degenerative Disc Disease Treatment Market, by Route of Administration
  • 1.4.2 Global Degenerative Disc Disease Treatment Market, by Drugs
  • 1.4.3 Global Degenerative Disc Disease Treatment Market, by End Use
  • 1.4.4 Global Degenerative Disc Disease Treatment Market, by Treatment Type
  • 1.4.5 Global Degenerative Disc Disease Treatment Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market at a Glance

• 2.1 Key Highlights

Chapter 3. Market Overview

• 3.1 Introduction
  • 3.1.1 Overview
    • 3.1.1.1 Market Composition and Scenario
• 3.2 Key Factors Impacting the Market
  • 3.2.1 Market Drivers
  • 3.2.2 Market Restraints
  • 3.2.3 Market Opportunities
  • 3.2.4 Market Challenges
• 3.3 Porter Five Forces Analysis

Chapter 4. Global Degenerative Disc Disease Treatment Market by Route of Administration

• 4.1 Global Oral Market by Region
• 4.2 Global Injectable Market by Region

Chapter 5. Global Degenerative Disc Disease Treatment Market by Drugs

• 5.1 Global NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Market by Region
• 5.2 Global Acetaminophen Market by Region
• 5.3 Global Muscle Relaxants Market by Region
• 5.4 Global Steroids Market by Region

Chapter 6. Global Degenerative Disc Disease Treatment Market by End Use

• 6.1 Global Hospitals Market by Region
• 6.2 Global Clinics Market by Region
• 6.3 Global Others Market by Region

Chapter 7. Global Degenerative Disc Disease Treatment Market by Treatment Type

• 7.1 Global Physical Therapy Market by Region
• 7.2 Global Occupational Therapy Market by Region
• 7.3 Global Special Exercises Market by Region
• 7.4 Global Weight Loss Surgery Market by Region
• 7.5 Global Medications Market by Region

Chapter 8. Global Degenerative Disc Disease Treatment Market by Region

• 8.1 North America Degenerative Disc Disease Treatment Market
  • 8.1.1 North America Degenerative Disc Disease Treatment Market by Route of Administration
    • 8.1.1.1 North America Oral Market by Region
    • 8.1.1.2 North America Injectable Market by Region
  • 8.1.2 North America Degenerative Disc Disease Treatment Market by Drugs
    • 8.1.2.1 North America NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Market by Country
    • 8.1.2.2 North America Acetaminophen Market by Country
    • 8.1.2.3 North America Muscle Relaxants Market by Country
    • 8.1.2.4 North America Steroids Market by Country
  • 8.1.3 North America Degenerative Disc Disease Treatment Market by End Use
    • 8.1.3.1 North America Hospitals Market by Country
    • 8.1.3.2 North America Clinics Market by Country
    • 8.1.3.3 North America Others Market by Country
  • 8.1.4 North America Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.1.4.1 North America Physical Therapy Market by Country
    • 8.1.4.2 North America Occupational Therapy Market by Country
    • 8.1.4.3 North America Special Exercises Market by Country
    • 8.1.4.4 North America Weight Loss Surgery Market by Country
    • 8.1.4.5 North America Medications Market by Country
  • 8.1.5 North America Degenerative Disc Disease Treatment Market by Country
    • 8.1.5.1 US Degenerative Disc Disease Treatment Market
      • 8.1.5.1.1 US Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.1.5.1.2 US Degenerative Disc Disease Treatment Market by Drugs
      • 8.1.5.1.3 US Degenerative Disc Disease Treatment Market by End Use
      • 8.1.5.1.4 US Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.1.5.2 Canada Degenerative Disc Disease Treatment Market
      • 8.1.5.2.1 Canada Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.1.5.2.2 Canada Degenerative Disc Disease Treatment Market by Drugs
      • 8.1.5.2.3 Canada Degenerative Disc Disease Treatment Market by End Use
      • 8.1.5.2.4 Canada Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.1.5.3 Mexico Degenerative Disc Disease Treatment Market
      • 8.1.5.3.1 Mexico Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.1.5.3.2 Mexico Degenerative Disc Disease Treatment Market by Drugs
      • 8.1.5.3.3 Mexico Degenerative Disc Disease Treatment Market by End Use
      • 8.1.5.3.4 Mexico Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.1.5.4 Rest of North America Degenerative Disc Disease Treatment Market
      • 8.1.5.4.1 Rest of North America Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.1.5.4.2 Rest of North America Degenerative Disc Disease Treatment Market by Drugs
      • 8.1.5.4.3 Rest of North America Degenerative Disc Disease Treatment Market by End Use
      • 8.1.5.4.4 Rest of North America Degenerative Disc Disease Treatment Market by Treatment Type
• 8.2 Europe Degenerative Disc Disease Treatment Market
  • 8.2.1 Europe Degenerative Disc Disease Treatment Market by Route of Administration
    • 8.2.1.1 Europe Oral Market by Country
    • 8.2.1.2 Europe Injectable Market by Country
  • 8.2.2 Europe Degenerative Disc Disease Treatment Market by Drugs
    • 8.2.2.1 Europe NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Market by Country
    • 8.2.2.2 Europe Acetaminophen Market by Country
    • 8.2.2.3 Europe Muscle Relaxants Market by Country
    • 8.2.2.4 Europe Steroids Market by Country
  • 8.2.3 Europe Degenerative Disc Disease Treatment Market by End Use
    • 8.2.3.1 Europe Hospitals Market by Country
    • 8.2.3.2 Europe Clinics Market by Country
    • 8.2.3.3 Europe Others Market by Country
  • 8.2.4 Europe Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.2.4.1 Europe Physical Therapy Market by Country
    • 8.2.4.2 Europe Occupational Therapy Market by Country
    • 8.2.4.3 Europe Special Exercises Market by Country
    • 8.2.4.4 Europe Weight Loss Surgery Market by Country
    • 8.2.4.5 Europe Medications Market by Country
  • 8.2.5 Europe Degenerative Disc Disease Treatment Market by Country
    • 8.2.5.1 Germany Degenerative Disc Disease Treatment Market
      • 8.2.5.1.1 Germany Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.2.5.1.2 Germany Degenerative Disc Disease Treatment Market by Drugs
      • 8.2.5.1.3 Germany Degenerative Disc Disease Treatment Market by End Use
      • 8.2.5.1.4 Germany Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.2.5.2 UK Degenerative Disc Disease Treatment Market
      • 8.2.5.2.1 UK Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.2.5.2.2 UK Degenerative Disc Disease Treatment Market by Drugs
      • 8.2.5.2.3 UK Degenerative Disc Disease Treatment Market by End Use
      • 8.2.5.2.4 UK Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.2.5.3 France Degenerative Disc Disease Treatment Market
      • 8.2.5.3.1 France Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.2.5.3.2 France Degenerative Disc Disease Treatment Market by Drugs
      • 8.2.5.3.3 France Degenerative Disc Disease Treatment Market by End Use
      • 8.2.5.3.4 France Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.2.5.4 Russia Degenerative Disc Disease Treatment Market
      • 8.2.5.4.1 Russia Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.2.5.4.2 Russia Degenerative Disc Disease Treatment Market by Drugs
      • 8.2.5.4.3 Russia Degenerative Disc Disease Treatment Market by End Use
      • 8.2.5.4.4 Russia Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.2.5.5 Spain Degenerative Disc Disease Treatment Market
      • 8.2.5.5.1 Spain Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.2.5.5.2 Spain Degenerative Disc Disease Treatment Market by Drugs
      • 8.2.5.5.3 Spain Degenerative Disc Disease Treatment Market by End Use
      • 8.2.5.5.4 Spain Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.2.5.6 Italy Degenerative Disc Disease Treatment Market
      • 8.2.5.6.1 Italy Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.2.5.6.2 Italy Degenerative Disc Disease Treatment Market by Drugs
      • 8.2.5.6.3 Italy Degenerative Disc Disease Treatment Market by End Use
      • 8.2.5.6.4 Italy Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.2.5.7 Rest of Europe Degenerative Disc Disease Treatment Market
      • 8.2.5.7.1 Rest of Europe Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.2.5.7.2 Rest of Europe Degenerative Disc Disease Treatment Market by Drugs
      • 8.2.5.7.3 Rest of Europe Degenerative Disc Disease Treatment Market by End Use
      • 8.2.5.7.4 Rest of Europe Degenerative Disc Disease Treatment Market by Treatment Type
• 8.3 Asia Pacific Degenerative Disc Disease Treatment Market
  • 8.3.1 Asia Pacific Degenerative Disc Disease Treatment Market by Route of Administration
    • 8.3.1.1 Asia Pacific Oral Market by Country
    • 8.3.1.2 Asia Pacific Injectable Market by Country
  • 8.3.2 Asia Pacific Degenerative Disc Disease Treatment Market by Drugs
    • 8.3.2.1 Asia Pacific NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Market by Country
    • 8.3.2.2 Asia Pacific Acetaminophen Market by Country
    • 8.3.2.3 Asia Pacific Muscle Relaxants Market by Country
    • 8.3.2.4 Asia Pacific Steroids Market by Country
  • 8.3.3 Asia Pacific Degenerative Disc Disease Treatment Market by End Use
    • 8.3.3.1 Asia Pacific Hospitals Market by Country
    • 8.3.3.2 Asia Pacific Clinics Market by Country
    • 8.3.3.3 Asia Pacific Others Market by Country
  • 8.3.4 Asia Pacific Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.3.4.1 Asia Pacific Physical Therapy Market by Country
    • 8.3.4.2 Asia Pacific Occupational Therapy Market by Country
    • 8.3.4.3 Asia Pacific Special Exercises Market by Country
    • 8.3.4.4 Asia Pacific Weight Loss Surgery Market by Country
    • 8.3.4.5 Asia Pacific Medications Market by Country
  • 8.3.5 Asia Pacific Degenerative Disc Disease Treatment Market by Country
    • 8.3.5.1 China Degenerative Disc Disease Treatment Market
      • 8.3.5.1.1 China Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.3.5.1.2 China Degenerative Disc Disease Treatment Market by Drugs
      • 8.3.5.1.3 China Degenerative Disc Disease Treatment Market by End Use
      • 8.3.5.1.4 China Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.3.5.2 Japan Degenerative Disc Disease Treatment Market
      • 8.3.5.2.1 Japan Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.3.5.2.2 Japan Degenerative Disc Disease Treatment Market by Drugs
      • 8.3.5.2.3 Japan Degenerative Disc Disease Treatment Market by End Use
      • 8.3.5.2.4 Japan Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.3.5.3 India Degenerative Disc Disease Treatment Market
      • 8.3.5.3.1 India Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.3.5.3.2 India Degenerative Disc Disease Treatment Market by Drugs
      • 8.3.5.3.3 India Degenerative Disc Disease Treatment Market by End Use
      • 8.3.5.3.4 India Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.3.5.4 South Korea Degenerative Disc Disease Treatment Market
      • 8.3.5.4.1 South Korea Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.3.5.4.2 South Korea Degenerative Disc Disease Treatment Market by Drugs
      • 8.3.5.4.3 South Korea Degenerative Disc Disease Treatment Market by End Use
      • 8.3.5.4.4 South Korea Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.3.5.5 Singapore Degenerative Disc Disease Treatment Market
      • 8.3.5.5.1 Singapore Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.3.5.5.2 Singapore Degenerative Disc Disease Treatment Market by Drugs
      • 8.3.5.5.3 Singapore Degenerative Disc Disease Treatment Market by End Use
      • 8.3.5.5.4 Singapore Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.3.5.6 Malaysia Degenerative Disc Disease Treatment Market
      • 8.3.5.6.1 Malaysia Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.3.5.6.2 Malaysia Degenerative Disc Disease Treatment Market by Drugs
      • 8.3.5.6.3 Malaysia Degenerative Disc Disease Treatment Market by End Use
      • 8.3.5.6.4 Malaysia Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.3.5.7 Rest of Asia Pacific Degenerative Disc Disease Treatment Market
      • 8.3.5.7.1 Rest of Asia Pacific Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.3.5.7.2 Rest of Asia Pacific Degenerative Disc Disease Treatment Market by Drugs
      • 8.3.5.7.3 Rest of Asia Pacific Degenerative Disc Disease Treatment Market by End Use
      • 8.3.5.7.4 Rest of Asia Pacific Degenerative Disc Disease Treatment Market by Treatment Type
• 8.4 LAMEA Degenerative Disc Disease Treatment Market
  • 8.4.1 LAMEA Degenerative Disc Disease Treatment Market by Route of Administration
    • 8.4.1.1 LAMEA Oral Market by Country
    • 8.4.1.2 LAMEA Injectable Market by Country
  • 8.4.2 LAMEA Degenerative Disc Disease Treatment Market by Drugs
    • 8.4.2.1 LAMEA NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Market by Country
    • 8.4.2.2 LAMEA Acetaminophen Market by Country
    • 8.4.2.3 LAMEA Muscle Relaxants Market by Country
    • 8.4.2.4 LAMEA Steroids Market by Country
  • 8.4.3 LAMEA Degenerative Disc Disease Treatment Market by End Use
    • 8.4.3.1 LAMEA Hospitals Market by Country
    • 8.4.3.2 LAMEA Clinics Market by Country
    • 8.4.3.3 LAMEA Others Market by Country
  • 8.4.4 LAMEA Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.4.4.1 LAMEA Physical Therapy Market by Country
    • 8.4.4.2 LAMEA Occupational Therapy Market by Country
    • 8.4.4.3 LAMEA Special Exercises Market by Country
    • 8.4.4.4 LAMEA Weight Loss Surgery Market by Country
    • 8.4.4.5 LAMEA Medications Market by Country
  • 8.4.5 LAMEA Degenerative Disc Disease Treatment Market by Country
    • 8.4.5.1 Brazil Degenerative Disc Disease Treatment Market
      • 8.4.5.1.1 Brazil Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.4.5.1.2 Brazil Degenerative Disc Disease Treatment Market by Drugs
      • 8.4.5.1.3 Brazil Degenerative Disc Disease Treatment Market by End Use
      • 8.4.5.1.4 Brazil Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.4.5.2 Argentina Degenerative Disc Disease Treatment Market
      • 8.4.5.2.1 Argentina Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.4.5.2.2 Argentina Degenerative Disc Disease Treatment Market by Drugs
      • 8.4.5.2.3 Argentina Degenerative Disc Disease Treatment Market by End Use
      • 8.4.5.2.4 Argentina Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.4.5.3 UAE Degenerative Disc Disease Treatment Market
      • 8.4.5.3.1 UAE Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.4.5.3.2 UAE Degenerative Disc Disease Treatment Market by Drugs
      • 8.4.5.3.3 UAE Degenerative Disc Disease Treatment Market by End Use
      • 8.4.5.3.4 UAE Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.4.5.4 Saudi Arabia Degenerative Disc Disease Treatment Market
      • 8.4.5.4.1 Saudi Arabia Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.4.5.4.2 Saudi Arabia Degenerative Disc Disease Treatment Market by Drugs
      • 8.4.5.4.3 Saudi Arabia Degenerative Disc Disease Treatment Market by End Use
      • 8.4.5.4.4 Saudi Arabia Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.4.5.5 South Africa Degenerative Disc Disease Treatment Market
      • 8.4.5.5.1 South Africa Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.4.5.5.2 South Africa Degenerative Disc Disease Treatment Market by Drugs
      • 8.4.5.5.3 South Africa Degenerative Disc Disease Treatment Market by End Use
      • 8.4.5.5.4 South Africa Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.4.5.6 Nigeria Degenerative Disc Disease Treatment Market
      • 8.4.5.6.1 Nigeria Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.4.5.6.2 Nigeria Degenerative Disc Disease Treatment Market by Drugs
      • 8.4.5.6.3 Nigeria Degenerative Disc Disease Treatment Market by End Use
      • 8.4.5.6.4 Nigeria Degenerative Disc Disease Treatment Market by Treatment Type
    • 8.4.5.7 Rest of LAMEA Degenerative Disc Disease Treatment Market
      • 8.4.5.7.1 Rest of LAMEA Degenerative Disc Disease Treatment Market by Route of Administration
      • 8.4.5.7.2 Rest of LAMEA Degenerative Disc Disease Treatment Market by Drugs
      • 8.4.5.7.3 Rest of LAMEA Degenerative Disc Disease Treatment Market by End Use
      • 8.4.5.7.4 Rest of LAMEA Degenerative Disc Disease Treatment Market by Treatment Type

Chapter 9. Company Profiles

• 9.1 Medtronic PLC
  • 9.1.1 Company overview
  • 9.1.2 Financial Analysis
  • 9.1.3 Segmental and Regional Analysis
  • 9.1.4 Research & Development Expenses
  • 9.1.5 Recent strategies and developments:
    • 9.1.5.1 Partnerships, Collaborations, and Agreements:
    • 9.1.5.2 Trail and Approvals:
  • 9.1.6 SWOT Analysis
• 9.2 AstraZeneca PLC
  • 9.2.1 Company Overview
  • 9.2.2 Financial Analysis
  • 9.2.3 Regional Analysis
  • 9.2.4 Research & Development Expenses
  • 9.2.5 SWOT Analysis
• 9.3 Pfizer, Inc.
  • 9.3.1 Company Overview
  • 9.3.2 Financial Analysis
  • 9.3.3 Regional & Segmental Analysis
  • 9.3.4 Research & Development Expense
  • 9.3.5 SWOT Analysis
• 9.4 Novartis AG
  • 9.4.1 Company Overview
  • 9.4.2 Financial Analysis
  • 9.4.3 Segmental and Regional Analysis
  • 9.4.4 Research & Development Expense
  • 9.4.5 Recent strategies and developments:
    • 9.4.5.1 Partnerships, Collaborations, and Agreements:
    • 9.4.5.2 Acquisition and Mergers:
  • 9.4.6 SWOT Analysis
• 9.5 Eli Lilly And Company
  • 9.5.1 Company Overview
  • 9.5.2 Financial Analysis
  • 9.5.3 Regional Analysis
  • 9.5.4 Research & Development Expenses
  • 9.5.5 SWOT Analysis
• 9.6 Spine Wave Inc.
  • 9.6.1 Company Overview
• 9.7 B. Braun Melsungen AG (Aesculap, Inc.)
  • 9.7.1 Company Overview
  • 9.7.2 Financial Analysis
  • 9.7.3 Segmental and Regional Analysis
  • 9.7.4 Research & Development Expenses
  • 9.7.5 SWOT Analysis
• 9.8 DiscGenics, Inc.
  • 9.8.1 Company Overview
• 9.9 Spine BioPharma Inc.
  • 9.9.1 Company Overview
• 9.10. Stryker Corporation
  • 9.10.1 Company Overview
  • 9.10.2 Financial Analysis
  • 9.10.3 Segmental and Regional Analysis
  • 9.10.4 Research & Development Expenses
  • 9.10.5 SWOT Analysis

Chapter 10. Winning Imperative of Degenerative Disc Disease Treatment Market